⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31757673 | 1.00 | — | — | |
| SCHEMBL22114021 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL2646864 | 0.98 | — | — | |
| SCHEMBL1556319 | 0.81 | — | — | |
| SCHEMBL2721193 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL1262556 | 0.79 | GABRR1 (0.37) | — | |
| SCHEMBL23948749 | 0.78 | — | — | |
| SCHEMBL7400822 | 0.78 | — | — | |
| SCHEMBL3394094 | 0.78 | CA1 (0.38) | — | |
| SCHEMBL13583797 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2246322-B1 | PROCESS FOR PRODUCING ALPHA-FLUORO-BETA-AMINO ACIDS | CENTRAL GLASS CO LTD (JP) | 2013-04-03 | — | — | EP | disclosed |
| US-8217196-B2 | Process for producing α-fluoro-β-amino acids | CENTRAL GLASS COMPANY, LIMITED (JP) | 2012-07-10 | — | — | US | disclosed |
| US-8217196-B2 | Process for producing α-fluoro-β-amino acids | CENTRAL GLASS COMPANY, LIMITED (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110015428-A1 | Process for Producing Alpha-Fluoro-Beta-Amino Acids | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-01-20 | — | — | US | disclosed |
| US-20110015428-A1 | Process for Producing Alpha-Fluoro-Beta-Amino Acids | CENTRAL GLASS COMPANY, LIMITED (JP) | 2011-01-20 | — | — | US | disclosed |
| EP-2246322-A1 | PROCESS FOR PRODUCING -FLUORO- -AMINO ACIDS | Central Glass Company, Limited (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-6953812-B2 | Glucagon antagonists/inverse agonists | NOVO NORDISK, INC. (DK) | 2005-10-11 | — | — | US | disclosed |
| US-20040024045-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2004-02-05 | — | — | US | disclosed |
| US-6562807-B2 | For prophylaxis and therapy of hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity | NOVO NORDISK A/S (DK) | 2003-05-13 | — | — | US | disclosed |
| EP-1296942-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | Novo Nordisk A/S (DK) | 2003-04-02 | — | — | EP | disclosed |
| US-20020143186-A1 | Glucagon antagonists/inverse agonists | PFIZER INC | 2002-10-03 | — | — | US | disclosed |
| WO-2002000612-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-01-03 | — | — | WO | disclosed |